WO2006087913A1 - 免疫賦活用組成物 - Google Patents
免疫賦活用組成物 Download PDFInfo
- Publication number
- WO2006087913A1 WO2006087913A1 PCT/JP2006/301661 JP2006301661W WO2006087913A1 WO 2006087913 A1 WO2006087913 A1 WO 2006087913A1 JP 2006301661 W JP2006301661 W JP 2006301661W WO 2006087913 A1 WO2006087913 A1 WO 2006087913A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bifidobacteria
- food
- production
- strain
- iga
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 230000005934 immune activation Effects 0.000 title abstract 2
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 115
- 238000004519 manufacturing process Methods 0.000 claims abstract description 106
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 72
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 66
- 230000003248 secreting effect Effects 0.000 claims abstract description 35
- 230000001939 inductive effect Effects 0.000 claims abstract description 29
- 210000004027 cell Anatomy 0.000 claims description 84
- 230000003308 immunostimulating effect Effects 0.000 claims description 71
- 102400001107 Secretory component Human genes 0.000 claims description 66
- 235000013305 food Nutrition 0.000 claims description 61
- 239000000047 product Substances 0.000 claims description 49
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 239000012228 culture supernatant Substances 0.000 claims description 23
- 210000001986 peyer's patch Anatomy 0.000 claims description 21
- 235000013376 functional food Nutrition 0.000 claims description 19
- 235000013361 beverage Nutrition 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 12
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 239000013589 supplement Substances 0.000 claims description 6
- 235000008452 baby food Nutrition 0.000 claims description 4
- 235000015140 cultured milk Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 230000000474 nursing effect Effects 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 210000004400 mucous membrane Anatomy 0.000 abstract description 4
- 230000014509 gene expression Effects 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 34
- 239000002609 medium Substances 0.000 description 31
- 239000002953 phosphate buffered saline Substances 0.000 description 28
- 239000000306 component Substances 0.000 description 27
- 238000005259 measurement Methods 0.000 description 20
- 210000002429 large intestine Anatomy 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 210000000813 small intestine Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 210000003405 ileum Anatomy 0.000 description 10
- 230000036737 immune function Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 241001608472 Bifidobacterium longum Species 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 229940009291 bifidobacterium longum Drugs 0.000 description 7
- -1 culture Substances 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000001605 fetal effect Effects 0.000 description 7
- 235000013350 formula milk Nutrition 0.000 description 7
- 210000003563 lymphoid tissue Anatomy 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 210000004180 plasmocyte Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 241000286268 Bifidobacterium bifidum ATCC 29521 = JCM 1255 = DSM 20456 Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001655328 Bifidobacteriales Species 0.000 description 4
- 241000186012 Bifidobacterium breve Species 0.000 description 4
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000000621 bronchi Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000002229 urogenital system Anatomy 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000020299 breve Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000008944 intestinal immunity Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- IOCJWNPYGRVHLN-MMALYQPHSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CSSC[C@H](N)C(O)=O IOCJWNPYGRVHLN-MMALYQPHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- AANLCWYVVNBGEE-IDIVVRGQSA-L Disodium inosinate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 AANLCWYVVNBGEE-IDIVVRGQSA-L 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000033301 Ileal fistula Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 101710175727 Peptide chain release factor 1 Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000012174 carbonated soft drink Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000020152 coffee milk drink Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000013890 disodium inosinate Nutrition 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940007062 eucalyptus extract Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- JAOZKJMVYIWLKU-UHFFFAOYSA-N sodium 7-hydroxy-8-[(4-sulfonaphthalen-1-yl)diazenyl]naphthalene-1,3-disulfonic acid Chemical compound C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)O)N=NC3=C(C=CC4=CC(=CC(=C43)S(=O)(=O)O)S(=O)(=O)O)O.[Na+] JAOZKJMVYIWLKU-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000015040 sparkling wine Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- the present invention relates to an immunostimulatory composition characterized by containing bifidobacteria belonging to bifidobacterium bifidum and / or a processed product of the bifidobacteria, and
- the present invention relates to foods and drinks and pharmaceutical compositions useful for immunostimulation.
- the mucous membrane surface of the bronchi, digestive tract, genitourinary system, etc. is mainly composed of secretory IgA to protect the body against many foreign antigens including microorganisms such as bacteria and viruses and food proteins.
- secretory IgA is a dimer IgA (dimeric IgA: 2IgA'J) containing J chain and a secretory component (SC: secretory com ponent, or secretory piece). 2IgA'J'SC), which is abundant in saliva, tears, nasal discharge, milk, and secretions from the bronchi and intestinal tract.
- mucosa-related lymphoid tissue Such lymphoid tissue on the mucosal surface is called mucosa-related lymphoid tissue and plays a central role in inducing IgA production.
- antigen-stimulated activated B-cell force such as Peyer's patch, which is a typical mucosa-related lymphoid tissue of the intestinal tract, is returned not only to the intestinal tract but also to the exocrine glands and bronchi It is distributed on the mucosal surface of the genitourinary system and differentiates into plasma cells that are IgA-producing cells to produce dimeric IgA.
- the dimeric IgA produced in this way is combined with secretory components produced in the mucosal epithelial cells to form secretory IgA, which is secreted from the mucosa into the lumen and ex vivo.
- secretory component is an essential component for secreting dimeric IgA into the lumen or outside the living body.
- a food ingredient or composition that induces and establishes the production of dimeric IgA and the production of secretory components in the mucous membranes of the bronchi, gastrointestinal tract, urogenital system, etc. It can be expected to increase the amount of secretory IgA secreted from the mucous membrane to the lumen and in vitro to enhance the defense ability.
- such enhancement of the body defense ability by mucosal immunity is particularly useful in preventing pathogens from entering the body and preventing the development of food allergies. is there.
- Patent Document 1 As substances that enhance the production of secretory IgA, for example, the present inventors have found a furato-oligosaccharide and a composition thereof (Patent Document 1). This furato-oligosaccharide is one of the few food ingredients reported for its effect on the production of secretory ingredients. On the other hand, it is known that bifidobacteria bifidobatterium longumya bifidobatterium breve induces IgA production in Peyer's patch cells (Patent Document 2).
- Bifidobacterium longum OLB 6001 strain isolated from adult feces has the ability to induce IgA production (Non-patent Document 1).
- This bifidobacteria Bifidoba cterium longum OLB 6001 strain is the same as that reported by the present inventors group as Bifidobatterium longum No. 7 (Accession No. FERM P-13610) (patent document) 3).
- further appearance of an immunostimulatory composition having a higher immunostimulatory effect than those of bifidobacteria is still desired.
- Patent Document 1 Japanese Unexamined Patent Publication No. 2003-201239
- Patent Document 2 Japanese Patent Publication No. 7-106142
- Patent Document 3 Japanese Patent Laid-Open No. 7-69907
- Non-special reference 1 Takahashi T., NaKagawa ⁇ ⁇ , Nara ⁇ ⁇ , Yajima ⁇ . And Kuwata T. Biosci Biotechnol Biochem 62 (1), (1998) p.10-15
- An object of the present invention is to provide an immunostimulatory composition, and a food and drink and a pharmaceutical composition useful for immunostimulation.
- the present inventors have found that the production of secretory components and the intestinal mucosal system among bifidobacteria belonging to Bifidobacterium bifidum.
- the present invention was completed by succeeding in obtaining a plurality of strains useful in immunostimulation, which can promote both production of dimer IgA in. That is, the present invention includes the following.
- [0007] Secretory synthesis that increases secretory component production in intestinal epithelial cells by at least 1.2 times An immunostimulatory composition comprising bifidobacteria belonging to Bifidobacterium bifidum and / or a processed product of the bifidobacteria having an ability to induce partial production.
- the Bifidobacterium is a strain of Bifidobacterium bifidum OLB 6377 (accession number NITE BP-
- a food or drink comprising the immunostimulatory composition according to any one of [1] to [4] above.
- a pharmaceutical composition comprising the immunostimulatory composition according to [1] to [4] above.
- Bifidobacterium bifi dum OLB 6377 strain (Accession number ⁇ BP-30) or Bifidobacterium bifidum OLB 6378 strain (Accession number NITE BP-31) for producing immunostimulating foods and drinks or pharmaceutical compositions Use of.
- the immunostimulatory composition of the present invention can promote the production of secretory components in epithelial cells, and bifidobacteria (Bifidobataterum longumya bifu) that have been reported to have an immunostimulatory effect. It can induce IgA production in Peyer's patch cells considerably more strongly than Idbaterium (Breve etc.). Therefore, the immunostimulatory composition of the present invention is In particular, it is very useful in stimulating mucosal immunity. Furthermore, the food / beverage products and the pharmaceutical composition of the present invention contain an immunostimulatory composition derived from bifidobacteria that humans have taken as food for many years, and therefore have less risk of causing side effects.
- Bifidobacterium bifidum OLB 6377 strain accesion No. NITE BP-30
- Bifidobacterium bifidum OLB 6378 strain accesion No. NITE BP-311
- the ability to promote the production of secretory components can be achieved. It is possible to produce an immunologically effective composition capable of inducing IgA production several times stronger than conventional bifidobacteria.
- FIG. 1 shows the ability to induce IgA production when a lymphocyte group derived from mouse Peyer's patches is cultured with various bifidobacteria in the presence of anti-CD3 antibody.
- n 3, the value is expressed as the average soil standard deviation.
- FIG. 2 Shows the effect of disrupted Bifidobacterium bifidum OLB 6377 strain on secretory component production from HT-29.
- FIG. 3 The effect of disrupted Bifidobacterium bifidum OLB 6378 strain on the production of secretory components from HT-29 cells.
- the sample was added to the medium so as to be 500 ⁇ g / ml and cultured for 48 hours.
- n 3. The value is a relative value when the control is 1, and is expressed as an average soil standard deviation.
- FIG. 5 shows the effect of disrupted Bifidobacterium bifidum OLB 6378 strain on the expression level of secretory component genes in the small and large intestines.
- the bar is the average soil SD (standard deviation) The relative value indicated by
- an immunostimulatory composition is produced using bifidobacteria belonging to Bifidobacterium bifidum, which have a secretory component production-inducing ability and a high IgA production-inducing ability.
- Bifidobacterium bifidum to which the bifidobacteria used in the present invention belongs is one species of the genus Bifidobacteria.
- Bifidobacteria classified as Bifidobacterium 'Bifidum' in the present invention can be identified according to the usual taxonomic criteria, but molecular biology techniques frequently used in recent years, for example, Bifidobacterium 'Bifidum' It can also be identified by a method using a specific DNA probe (intestinal floracin deposit 8 “molecular ecological detection and identification of intestinal flora”) or DNA homology with a standard strain.
- secretory component production inducing ability refers to the ability to promote secretion of secretory components from mucosal epithelial cells (for example, but not limited to, intestinal epithelial cells). This ability to induce secretory component production is, for example, when the amount of secretory component secreted from mucosal epithelial cells in contact with bifidobacteria or a treated product of bifidobacteria is compared with that of a control experiment group without using bifidobacteria, etc. Of the secretory component concentration or the relative value of the secretory component amount.
- the bifidobacteria used in the present invention is selected from among the bifidobacteria belonging to bifid butterium bifidum that can increase secretory component production in intestinal epithelial cells by at least 1.2 times. It is preferable that The amount of secretory component produced can be measured in vitro, for example, as described in the Examples below. [0025] Selection of such Bifidobacteria is not limited, but can be performed, for example, based on the Atsy method described in the Examples of the present specification.
- bifidobacteria belonging to bifidobatterium 'bifidum are cultured in an anaerobic EG medium prepared by changing glucose to ratatoses, and the cells in the resulting culture are washed, Next, heat treatment and ultrasonic crushing are performed to obtain a crushed cell body.
- This cell disruption product is added to a medium inoculated with a human intestinal epithelial cell-derived cell line (eg, HT-29 cells), preferably cultured at 37 ° C for 48 hours, and then secreted components in the culture supernatant. Measure the concentration.
- a suspension of cultured cells in PBS (-) may be added directly to the above medium.
- the Bifidobacterium strain when the relative value S1.5 obtained by performing the above-mentioned assay using a certain Bifidobacterium strain, the Bifidobacterium strain has the ability to increase the secretory component production from intestinal epithelial cells by 1.5 times. And can be selected as the bifidobacteria of the present invention. Since this culture system does not contain plasma cells (IgA-producing cells), the secretory component does not bind to IgA and is isolated alone in the culture supernatant.
- the ability to induce secretory component production of bifidobacteria used in the present invention is also supported by the effect of increasing the expression level of the secretory component gene in the intestine.
- the bifidobacteria used in the present invention can preferably increase the expression level of the secretory component gene by at least 2.0 times.
- the increase in the expression level of the secretory component gene by the bifidobacteria of the present invention is as follows: zj ⁇ ⁇ ⁇ or Otsukiyasu, secreted, component component gene 5 plgR ⁇ oden olymeric immunoglobulin receptor gene; GeneiD: 18703; Shimada S. et al "J Immunol.
- mRNA eg accession number BC013556 [international nucleotide sequence data Base]
- the amount of mRNA derived from the plgR gene is prepared by reverse transcription PCR using oligo-dT primers using total RNA extracted from tissues of the small intestine (eg, ileum, jejunum, etc.) or large intestine (eg, proximal colon). Then, by using the obtained cDNA as a saddle and performing real-time PCR using a plgR gene-specific primer pair, it can be determined from the amount of the amplified product detected.
- the intestinal tissue to be used for measuring the expression level of the plgR gene may be organ-cultured to make the measurement conditions uniform. It is also preferable to use GAPDH gene, / 3actin gene, etc. as an internal standard for real-time PCR. These genes can also be obtained as commercially available hybridization probes (Alied Biosystems, Stratagene, etc.), and they can be suitably used as internal standards.
- the bifidobacteria used in the present invention can also increase the expression level of the interferon regulatory factor 1 gene (IRF-1 gene) in the intestine as well as increase the expression level of the secretory component gene as described above. It is preferable that The bifidobacteria used in the present invention can preferably increase the expression level of the IRF-1 gene in the intestinal tissue by at least 1.5 times.
- IRF-1 gene interferon regulatory factor 1 gene
- the increase in the expression level of the IRF-1 gene by the bifidobacteria of the present invention is specifically the IRF-1 gene (interferon regulatory factor 1; GeneID: 16362) force-expressed mRNA in the small or large intestine (for example, Session number NM008390 [International Base Sequence Data Base]) percentage (relative to total mRNA) can be confirmed as an increase.
- the amount of mRNA derived from the RF-1 gene can be determined, for example, by using oligo dT primers with the total RNA extracted from tissues of the small intestine (eg, ileum, jejunum, etc.) or large intestine (eg, proximal large intestine) as a saddle type.
- changes in the amount of mRNA derived from the IRF-1 gene can be analyzed using a DNA microarray using cRNA prepared using the entire RNA as a saddle type. It is.
- the intestinal tissue used for measuring the expression level of the IRF-1 gene may be organ-cultured in order to make the measurement conditions uniform.
- IgA production inducing ability refers to the ability to promote the secretion of IgA from plasma cells present in mucosa-related lymphoid tissues (for example, but not limited to intestinal mucosa).
- This ability to induce IgA production is, for example, that when the amount of IgA secreted into the mucosa-associated lymphoid tissue that has been contacted with bifidobacteria or a treated product of bifidobacteria is compared with a control experiment group that does not use bifidobacteria, etc. This can be shown by the rate of increase in IgA concentration.
- this IgA production-inducing ability may be indicated by the concentration of IgA produced from IgA-producing cells derived from mucosa-associated lymphoid tissue in a specific accessory system.
- the bifidobacteria of the present invention has a higher ability to induce IgA production than the bifidobacteria that have been reported to induce IgA production. More specifically, the “high IgA production induction positive” possessed by the bifidobacteria of the present invention refers to the IgA production amount per 5 ⁇ 10 5 Peyer's patch cells in the presence of anti-CD3 antibody in an in vitro experimental system.
- the bifidobacteria used in the present invention is, among bifidobacteria belonging to Bifidobacterium bifidum, for example IgA per 5 ⁇ 10 5 Peyer's patch cells in the presence of anti-CD3 antibody in the following Atsy system. It is preferable to select bacteria that produce at least 10 / ig / ml.
- the assay based on the amount of IgA produced for selection of bifidobacteria is not limited, but can be performed as follows, for example, based on the description in the Examples of the present specification. Briefly, first, bifidobacteria belonging to bifidobatterium 'bifidum are cultured in an anaerobic EG medium prepared by changing the gnole course to ratatoose, and then the cells in the resulting culture After washing, the cells are fixed with, for example, 4% formalin-PBS. The fixed cells are subjected to formalin removal as necessary, and then the concentration of the bacterial solution is adjusted so that the turbidity at 660 nm is 1.6.
- mice Lymphocytes containing T cells and B cells for example, 2% urushi fetal serum-containing RPM to 1640 medium
- Peyer's patches collected from the mice Lymphocytes containing T cells and B cells passed through a 150 gauge sterile stainless steel sieve, washed and resuspended in medium.
- the same control was used except that Bifidobacterium longum OLB 6001 strain or Bifidobacterium breve strain (Accession No.FERM BP-2824) was used instead of the bifidobacteria in the experimental group.
- Bifidobacterium longum OLB 6001 strain or Bifidobacterium breve strain accesion No.FERM BP-2824
- the amount of IgA in the culture supernatant of the control group in this control experiment group was set to 1, and the amount of IgA in the culture supernatant of the experiment group was converted to a relative value.
- the ability of Bifidobacterium used in the present invention to induce IgA production is 2 to 10 times, preferably 2.4 to 5 times, that of IgA production in Peyer's patch cells in the presence of anti-CD3 antibody, for example, compared to Bifidobacterium longum OLB 6001 strain. It has the ability to induce IgA production.
- Bifidobacterium strains that can be particularly preferably used in the present invention are the Bifidobacterium bifidum OLB 6377 strain and the Bifidobacterium bifidum OLB 6378 strain independently isolated from the feces of the infant by the present inventors. All of these strains have been identified as belonging to Bifido Batterium 'Bifidum by investigating with a strain-specific DNA probe.
- these strains are also capable of inducing secretory component production by the above-mentioned assay, and are 2-5 times higher than conventional bifidobacteria, IgA It has been confirmed that it has a production-inducing ability.
- mutant strains obtained from these strains can also be suitably used in the present invention as long as they have secretory component production-inducing ability and high IgA production-inducing ability.
- a medium usually used for culture of bifidobacteria can be used. That is, any medium can be used as long as it contains a nitrogen source, inorganic substances and other nutrients in addition to the main carbon source. Even better growth is obtained when sulfur-containing amino acids such as cystine or methionine are added.
- As the carbon source ratatoses, gnolesose, sucrose, fructose, galactose, molasses, etc. can be used according to the assimilation ability of the bacteria used.
- the nitrogen source organic nitrogen-containing substances such as casein hydrolyzate, whey protein hydrolyzate, and soy protein hydrolyzate can be used.
- meat extract, fish extract, yeast extract, etc. are used as growth promoters.
- the composition containing the bifidobacteria of the present invention as described above can be used as an immunostimulatory composition.
- a composition containing the processed product of the bifidobacteria of the present invention may be used as the immunostimulatory composition.
- the immunostimulatory composition of the present invention induces (promotes) the production of secretory components from mucosal epithelial cells such as intestinal epithelial cells, and also produces IgA in mucosal-related lymphoid tissues including neural plate cells. To a high level.
- an immunostimulatory action such as suppression of infection with a pathogen can be imparted to a food or drink or a pharmaceutical composition.
- the immunostimulatory composition is not limited, and may be in any form such as liquid, gel, powder, granule, solid, capsule, or tablet.
- the bifidobacteria of the present invention used in the immunostimulatory composition of the present invention may be a living cell, a dead cell, a wet cell, or a dry cell.
- the term “bifidobacteria” means both a strain and a cell of bifidobacteria.
- the "processed product" of bifidobacteria is not limited, but for example, bifidobacteria suspension (suspension), culture (cells, culture supernatant and medium) Contains ingredients ), Culture supernatant (from which the solid content has been removed from the culture), fermented product (raw milk, skim milk powder or soy milk, etc.
- the maximum number of cells contained in the processed bifidobacteria of the present invention is not particularly limited, but is usually about 4 X 10 1Q / g for the concentrate and about 5 X 10 "/ g for the dried product. Degree.
- the secretory component secreted into the gastrointestinal tract is considered to bind to infectious Escherichia coli and toxogenic clostridium cells alone and suppress infection of these pathogenic bacteria (J. Med. Biol. 1995). , 42: 3-9; J. Med. Microbiol. 1998, 47: 879-888). Therefore, the composition for immunostimulation of the present invention has an effect of reducing the risk of infection by infectious pathogens such as infectious Escherichia coli and Toxigenic Clostridium by promoting the production of secretory components.
- secretory IgA production from intestinal mucosal epithelial cells in vitro involves both production of IgA from plasma cells in the intestinal mucosa and production of secretory components in intestinal epithelial cells. It is known to play an important role. In fact, in experimental animals in which the gene for the secretory component is deficient, IgA that should be secreted into the intestinal lumen accumulates in the serum (J Exp Med 1999; 190: 915-22). It has also been suggested that environmental stimuli are involved in the expression of secretory components, and a decrease in the expression of secretory components due to malnutrition has been reported (Lab Invest 19 98; 78: 1255-66). The utilization composition exhibits a secretory component production-inducing ability and has a high ability to induce IgA production. It is thought that the production of A can be promoted.
- the present invention also relates to a method for improving the immunity of a subject by administering (preferably orally administering) the immunostimulatory composition according to the present invention to the subject.
- the immunostimulatory composition preferably, both the production of secretory component and the production of IgA are promoted in the administered subject, and as a result, the production of secretory IgA is promoted.
- the subject to which the immunostimulatory composition is administered is the same as the subject of administration of the pharmaceutical composition described below. Examples of suitable subjects include pregnant women, lactating women, infants, the elderly, and patients with impaired immune function.
- the dose of the immunostimulatory composition of the present application can follow the dose of the pharmaceutical composition described below.
- the present invention also relates to a Bifidobacterium having a secretory component production-inducing ability and a high IgA production-inducing ability, to foods and drinks to which an immunostimulating composition containing bifidobacteria belonging to bifidum and Z or a processed product of the bifidobacteria is added.
- food and beverage includes, but is not limited to, beverages, foods and functional foods.
- the food or drink containing the immunostimulatory composition of the present invention is not particularly limited.
- beverages containing the immunostimulatory composition of the present invention include fermented milk (such as yogurt), lactic acid bacteria beverages, milk beverages (such as coffee milk and fruit milk), tea-based beverages (such as green tea, tea and oolong tea), fruits and vegetables
- beverages such as beverages containing fruit juices such as oranges, apples and grapes, and vegetable juices such as tomatoes and carrots, alcoholic beverages (beer, sparkling wine, wine, etc.), carbonated beverages and soft drinks be able to.
- existing reference books such as “Latest 'Soft Drinks” (2003) (Kotsu Co., Ltd.) can be referred to.
- the food containing the immunostimulatory composition of the present invention is not particularly limited, and may be a fresh food or a processed food.
- a fresh food or a processed food For example, pudding, jelly, ice cream, cake, candy, pasta, udon, kamaboko, ham, soy sauce, dressing, mayonnaise, tofu, soup, bread, fish fillet, processed meat, vegetables, mushrooms Can be illustrated.
- Particularly preferred foods in the present invention include fermented milk and lactic acid bacteria beverages that can deliver the bifidobacteria of the present invention to the intestines alive.
- Functional food is particularly preferred as a food or drink containing the immunostimulatory composition of the present invention.
- Preferred functional foods of the present invention further include supplements for infants and infants with immature immune function development, and maternal supplements for breastfeeding for the purpose of enhancing or restoring immune functions, Includes elderly and sick supplements
- the functional food of the present invention is preferably useful for immunostimulation.
- Functionality of the present invention Food is an indicator of improved immune function, preferably improved intestinal immunity (mucosal immunity) (for example, increased production of IgA, increased production of secretory components, increased amount of secretory IgA, The increase in the number of spheres etc.) may be useful for immunostimulation.
- the functional food of the present invention may be intended primarily for uses other than immunostimulation.
- the functional food of the present invention preferably, food for specified health use or conditional tokuho [food for specified health use]
- the functional food of the present invention is in the form of solid preparations such as tablets, granules, powders, pills and capsules, liquid preparations such as liquids, suspensions and syrups, or preparations such as gels. It may be in the form of a normal food or drink (for example, beverage, powdered tea leaves, confectionery, etc.).
- the amount of the immunostimulatory composition of the present invention added to food or drink is not particularly limited, and may vary depending on the case.
- the specific blending amount can be appropriately determined by those skilled in the art in consideration of the type of food and drink, the desired taste and texture.
- the immunostimulation is such that the total amount of bifidobacteria and / or processed products of the bifidobacteria in the added immunostimulatory composition is S, 0.001 to 100% by mass, especially 0.1 to 100% by mass.
- the blending amount of the composition for use is appropriate.
- the immunostimulating composition of the present invention may be contained in a food or drink by any appropriate method available to those skilled in the art. For example, after preparing the immunostimulatory composition of the present invention in a liquid, gel, solid, powder or granule, it may be blended with food or drink. Alternatively, the immunostimulatory composition of the present invention may be directly mixed or dissolved in the raw material of food and drink. The immunostimulatory composition of the present invention may be applied, coated, penetrated or sprayed on food and drink. The immunostimulatory composition of the present invention may be uniformly dispersed in food or drink, or may be unevenly distributed. Capsules containing the immunostimulating composition of the present invention may be prepared.
- the immunostimulating composition of the present invention is wrapped with an edible film or an edible coating agent. May be embedded. Moreover, after adding an appropriate excipient
- Additives include, but are not limited to, color formers (sodium nitrite, etc.), coloring agents (gardenia pigment, red 102, etc.), flavorings (orange flavors, etc.), sweeteners (stevia, astel palm, etc.) , Preservatives (sodium acetate, sorbic acid, etc.), emulsifiers (sodium chondroitin sulfate, propylene glycol fatty acid esters, etc.), antioxidants (EDTA disodium, vitamin C, etc.), pH regulators (taenoic acid, etc.), chemical Seasonings (such as sodium inosinate), thickeners (such as xanthan gum), swelling agents (such as calcium carbonate), antifoaming agents (such as phosphate phosphate), binders (such as sodium polyphosphate), nutrition enhancement Agents (calcium fortifier,
- the present invention relates to a pharmaceutical comprising, as an active ingredient, an immunostimulatory composition containing bifidobacteria belonging to bifidobacterium bifidum having secretory component production-inducing ability and high IgA production-inducing ability and / or a processed product of the bifidobacteria. It also relates to a composition.
- the pharmaceutical composition of the present invention may contain a carrier or additive acceptable in pharmaceutical preparations.
- carriers and additives include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, sodium alginate, water-soluble dextran, water-soluble dextrin.
- the pharmaceutical composition of the present invention further contains other pharmacological ingredients. May be.
- the pharmaceutical composition of the present invention is preferably administered orally or parenterally, particularly orally.
- the pharmaceutical composition of the present invention to be administered orally is an agent such as a solid preparation such as a tablet, granule, powder, pill or capsule, a gel preparation, or a liquid preparation such as a solution, suspension or syrup. It may be in shape. When used as a liquid preparation, when using the pharmaceutical composition of the present invention, it may be supplied as a dry product intended to be redissolved.
- the oral solid preparation may contain additives such as binders, excipients, lubricants, disintegrants, wetting agents and the like generally used in pharmacy.
- Oral liquid preparations may contain additives such as stabilizers, buffers, taste-masking agents, preservatives, fragrances, and coloring agents that are commonly used in pharmacology.
- the pharmaceutical composition of the present invention preferably exhibits an immunostimulatory action.
- the pharmaceutical composition of the present invention may be one obtained by adding an immunostimulatory action to a pharmaceutical composition for another therapeutic use containing other pharmacological substances.
- the pharmaceutical composition of the present invention is preferably an immunostimulator.
- the pharmaceutical composition of the present invention can reinforce the immune system, particularly the mucosal immune system, by significantly increasing IgA production in the mucosal immune system and increasing the production of secretory components.
- the pharmaceutical composition of the present invention can be used for the purpose of, for example, enhancing the ability to protect against pathogen infection.
- the dosage of the pharmaceutical composition of the present invention varies depending on the age and weight of the administration subject, the administration route, and the number of administrations, and can be varied widely within the discretion of those skilled in the art.
- the dose of bifidobacteria and / or processed products of the bifidobacteria contained in the immunostimulatory composition in the pharmaceutical composition should be 1 to 1000 mg / kg / day. It is right.
- the pharmaceutical composition of the present invention may be administered in a single dose, or may be administered repeatedly at intervals of 6 to 8 hours.
- Subjects to which the pharmaceutical composition of the present invention is administered are mammals including humans, domestic animals, pets, experimental (test) animals and the like.
- infants with undeveloped immune function mammals whose immune function has declined due to aging or illness, constitutional or environmental immunity Mammals whose ability is likely to decline are preferred as subjects to which the pharmaceutical composition of the present invention is administered.
- the pharmaceutical composition of the present invention can be used very effectively for continuous use since it is less susceptible to side effects.
- Bifidobacterium longum OLB 6001 strain (Accession number FERM P-13610), Bifidobacterium bifidum OLB 6377 strain (Accession number NITE BP-30), Bifidobacterium bifidum OLB 6378 strain (Accession number NITE BP-31), Bifidobacterium breve strain (Accession number FERM BP-2824) and Bifidobacterium bifidum MEP170212 (formerly Bifidobacterium bifidum # 1 (Meiko) strain; this strain is owned by Meiji Dairies, Japan)
- the cells were cultured overnight at 37 ° C in the anaerobic EG medium prepared above.
- the anaerobic EG medium was prepared according to the following composition.
- the cells in the obtained culture were washed twice with cold PBS (-), suspended in a small amount of PBS (-), and suspended in an equal volume of 8% formalin-PBS to fix the cells. . From the fixed cells, formalin was removed by washing with cold PBS (-) on the day of the experiment for measuring the ability to induce IgA production.
- the bacterial solution was suspended in PBS and the turbidity at 660 mm was 1.6. The bacterial solution concentration was adjusted so that The bacterial solution thus obtained was called a formalin-treated bifidobacterial solution.
- the collected Peyer's plate is taken out on a petri dish containing RPM 1640 medium (Gibco) containing a small amount of 2% urinary fetal serum, chopped with a scalpel blade, and a plastic syringe handle (Terumo). ) And gradually unraveled.
- the cell suspension thus obtained was passed through a 150-gauge sterilized stainless steel sieve and further washed twice with RPMI-1640 medium containing 2% urine fetal serum.
- the cells were resuspended in RPMI-1 640 medium containing an appropriate amount of 2% fetal bovine serum to obtain a lymphocyte group (Peier plate cells) containing T cells and B cells.
- the obtained lymphocyte group was washed by changing the RPM 1640 medium twice and then confirming that 98% or more were viable cells using trypan blue. on 3072) at 5 X 10 5 per well.
- this 96-well microphone mouthplate add 100 ⁇ l of anti-CD3 antibody (CEDARLANE, No. CL7202AP, working concentration: 2.5 xg / ml) to each tool in advance and incubate for 2 hours at 37 ° C.
- Pre-coated with anti-CD3 antibody by washing once with ⁇ 1 PBS and then once with 200 ⁇ FCS ( ⁇ ) RPMI medium was used.
- a lymphocyte group was cultured in the presence of anti-CD3 antibody for 5 days in the same manner as above except that no formalin-treated bifidobacteria solution was added. The amount of IgA was measured in the same manner.
- Table 1 shows the IgA concentration in the culture supernatant measured as described above.
- the cells were cultured overnight in the anaerobic EG medium prepared as described above. Subsequently, the cells in the obtained culture were washed twice with cold PBS ( ⁇ ) and then suspended at 10 mg / ml in PBS ( ⁇ ). This suspension was heat-treated at 75 ° C for 60 minutes, and then applied to an ultrasonic crusher (BRANSON SONIFIE R250, Duty cycle: 60%, Output control: 2 micro tip limit). Got.
- each of the 12 well plates prepared above was added to the medium of 3 wells so that the cell disruption concentration was 50 to 500 xg / ml, and cultured at 37 ° C for 48 hours.
- PBS (-) [Dulbecco's Phosphate Buffered Saline from which Ca and Mg ions were removed] was used instead of the disrupted cells.
- the culture supernatant was collected from the obtained culture, and the concentration of secretory components in the culture supernatant was measured by ELISA.
- the ELISA plate tool was coated at 4 ° C with a polyclonal antibody against human secretory component (DAK ⁇ , diluted 1000-fold with PBS (-)), and then 0.01% tween Wash with 20 PBS (-), then add 1% sushi serum albumin (BSA) _PBS (-) for 1 hour at room temperature Incubated and blocked. Next, 50 ⁇ of each culture supernatant obtained above was added to each well of the plate as a sample and incubated at room temperature for 1 hour.
- DAK ⁇ polyclonal antibody against human secretory component
- PBSA sushi serum albumin
- the light intensity was measured. The measurement results are shown as relative values when the secretory component production of the control is 1.
- Table 3 and Fig. 3 show the measurement results of the secretory component when Bifidobacterium bifidum OLB 6378 strain was added to the medium at 500 ⁇ g / ml in the above measurement. [Table 3]
- Bifidobacterium bifidum MEP170212 and Bifidobacterium bifidum MEP170222 showed no increase in secretory component production even at a relatively high concentration of 250 ⁇ g / ml. This indicates that Bifidobacterium belonging to Bifidobacterium bifidum does not necessarily have the ability to enhance secretory component production.
- the ileum and proximal large intestine were excised from BALB mice within 24 hours after delivery and were used for examination. That is, a tissue piece having a width of about 2 to 4 mm was prepared by slicing the ileum and the proximal large intestine. The tissue piece was cut longitudinally in a sheet shape on glass filter paper, and the surface on the muscle plate side was brought into close contact with the glass filter paper.
- RNA of cultured tissue was extracted using an RNA purification kit (QIAGEN, RNeasy mini kit), and cDNA was prepared using an oligo dT primer (INVITROGEN) as a cage. Furthermore, the cDNA is used as a saddle and PCR primers (5, -AGGCAATGACAACATGGGG-3, (SEQ ID NO: 1), and 5, _ATGTCA GCTTCCTCCTTGG-3 '(SEQ ID NO: 2)) specific to the plgR gene (secretory component gene) The real-time PCR to be used was measured using LightCycler (Roche), and the expression level of plgR gene in cDNA was measured.
- RNA purification kit QIAGEN, RNeasy mini kit
- cDNA was prepared using an oligo dT primer (INVITROGEN) as a cage. Furthermore, the cDNA is used as a saddle and PCR primers (5, -AGGCAATGACAACATGGGG-3, (SEQ ID NO: 1), and
- the plgR gene expression level measured for each sample is the GAPDH gene (PCR primer, 5'-TGAACGGGAAGCTCACTGG-3 '(SEQ ID NO: 3), and 5'-TCC ACCACCCTGTTGCTGTA-3' ( Using the expression level detected by the same method using SEQ ID NO: 4), correction was performed according to the following calculation formula.
- plgR gene relative expression level plgR gene expression level / GAPDH gene expression level
- the gene expression level of the plgR gene (secretory component gene) was increased 2.9-fold in the ileum (lower part of the small intestine) and 2.4-fold in the proximal large intestine (the first part of the large intestine).
- the increase in the large intestine was confirmed to be significant (P ⁇ 0.05) by Mann-Whitney U test. From these results, it was shown that Bifidobacterium bifidum enhances the expression of secretory component genes in the small and large intestines.
- Example 4 Measurement of expression levels of secreted component genes and IRF-1 gene expression in cultured tissues of small intestine and large intestine organs treated with disrupted bifidobacteria by DNA microarray from BALB mice on embryonic day 18 The ileum and proximal colon were removed and organ-cultured for use.
- a tissue piece having a width of about 2 to 4 mm was prepared by cutting the ileum and the proximal large intestine into round slices. The tissue piece was cut vertically in a sheet shape on glass filter paper, and the surface on the muscle plate side was brought into close contact with the glass filter paper.
- crushed bacterial cells derived from B. bifidum OLB 6378 prepared according to "1.
- GeneChip Expression 3 -Amplincation CDNA was synthesized using Reagent One-ycle cDNA Synthesis Kit (Affymetrix) and GeneChip Eukaryotic Poly-A RNA Control Kit (Affymetrix), and then purified using GeneChip Cleanup Module (Affymetrix) GeneChip Expression 3-Amplification Reagent IVT labeling Kit (Affymet rix) was used for in vitro transcription reaction. After cRNA was purified using GeneChip Cleanup Module (Affymetrix), the cRNA was fragmented with a fragmentation buffer (Affimetrix) to obtain a fragmented cRNA. Fragmented cRNA was used for analysis by DNA Ar ray system (Affymetrix).
- a mouse genome MG U74Av2 set (Affymetri X) containing about 36000 kinds of mouse genes was used. Variations between experiments were corrected using the ratio of gene expression to internal control. The effect of treatment with B. bifidum OLB 6378 on the expression level of each gene was expressed as a ratio to the expression level of each gene in the control experiment (PBS (-) treatment).
- Example 3 As shown in Table 6, when the cell disruption of Bifidobacterium bifidum OLB 637 strain 8 prepared according to Example 2 was added at a cell disruption concentration of 500 / g / ml, The results of Example 3 showed a 2.0-fold increase in secretory component gene (plgR gene) expression in the intestine (lower part of the small intestine) and 6.1-fold in the proximal large intestine (the first part of the large intestine) Almost matched.
- plgR gene secretory component gene
- Bifidobacterium bifidum OLB 6378 strain disrupted cells increased IRF-1 gene expression by 1.5 times in the ileum and 4.0 times in the proximal large intestine (the first part of the large intestine) compared to the control. It was seen.
- Bifidobacterium bifidum OLB 6378 strain and Bifidobacterium bifidum JCM 1255 T strain was measured and compared.
- Bifidobacterium bifidum JCM 1255 T strain was obtained as a comparative strain from the Independent Administrative Law, Bioresource Center, Microbial Materials Development Office (JCM) (2-1 Hirosawa, Wako, Saitama, Japan).
- Bifidobacterium bifidum OLB 6378 strain and Bifidobacterium bifidum JCM 1255 T strain were cultured overnight according to the procedure of Example 2, and then washed twice with cold PBS (-) and suspended in PBS (-).
- the immunostimulatory composition of the present invention can particularly enhance the function of the mucosal immune system by promoting the production of secretory components and highly promoting the production of IgA. Therefore, the immunostimulating composition of the present invention is useful for providing such an immune function enhancing action to foods and drinks and pharmaceutical compositions.
- foods and drinks and pharmaceutical compositions containing the immunostimulatory composition of the present invention are suitable for use in patients with low immune functions, such as infants, the elderly and the sick.
- the immunostimulatory composition of the present invention can be produced using the dead cells of the bifidobacteria of the present invention, it is also used by adding to products having biological standards such as infant formula. It can be used for various products regardless of product form.
- sequences of SEQ ID Nos: 1 to 4 are primers.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006800104644A CN101151041B (zh) | 2005-02-02 | 2006-02-01 | 免疫刺激用组合物 |
KR1020077020013A KR101234435B1 (ko) | 2005-02-02 | 2006-02-01 | 면역 부활용 조성물 |
EP06712804.1A EP1854467B8 (en) | 2005-02-02 | 2006-02-01 | Immunostimulatory composition |
CA2596680A CA2596680C (en) | 2005-02-02 | 2006-02-01 | Composition for immunostimulation |
US11/815,136 US7943124B2 (en) | 2005-02-02 | 2006-02-01 | Composition for immunostimulation |
JP2007503610A JP5001830B2 (ja) | 2005-02-02 | 2006-02-01 | 免疫賦活用組成物 |
AU2006215205A AU2006215205B2 (en) | 2005-02-02 | 2006-02-01 | Composition for immunostimulation |
HK08107058.6A HK1116667A1 (en) | 2005-02-02 | 2008-06-25 | Composition for immunostimulation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005026631 | 2005-02-02 | ||
JP2005-026631 | 2005-02-02 | ||
JP2005-256835 | 2005-09-05 | ||
JP2005256835 | 2005-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006087913A1 true WO2006087913A1 (ja) | 2006-08-24 |
Family
ID=36916323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/301661 WO2006087913A1 (ja) | 2005-02-02 | 2006-02-01 | 免疫賦活用組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7943124B2 (ja) |
EP (1) | EP1854467B8 (ja) |
JP (1) | JP5001830B2 (ja) |
KR (1) | KR101234435B1 (ja) |
CN (1) | CN101151041B (ja) |
AU (1) | AU2006215205B2 (ja) |
CA (1) | CA2596680C (ja) |
HK (1) | HK1116667A1 (ja) |
WO (1) | WO2006087913A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011525484A (ja) * | 2008-06-24 | 2011-09-22 | ネステク ソシエテ アノニム | プロバイオティクス、分泌型IgA及び感染症 |
JP2011525483A (ja) * | 2008-06-24 | 2011-09-22 | ネステク ソシエテ アノニム | プロバイオティクス、分泌型IgA及び炎症 |
WO2012029367A1 (ja) | 2010-08-31 | 2012-03-08 | 国立大学法人新潟大学 | 腸管免疫調整剤 |
WO2014119605A1 (ja) * | 2013-01-29 | 2014-08-07 | 日東薬品工業株式会社 | ビフィズス菌を含有する安定な組成物 |
WO2016194692A1 (ja) * | 2015-05-29 | 2016-12-08 | 株式会社明治 | 抗う蝕剤及び抗う蝕用組成物 |
WO2018190407A1 (ja) * | 2017-04-14 | 2018-10-18 | 株式会社明治 | Toll様受容体2活性化用組成物 |
WO2020009135A1 (ja) * | 2018-07-03 | 2020-01-09 | 学校法人北里研究所 | インフルエンザの重症化を抑制するための抗インフルエンザウイルス剤 |
JP2022552721A (ja) * | 2019-10-18 | 2022-12-19 | ゲノム アンド カンパニー | ビフィドバクテリウム・ビフィダムを含む免疫力増強または改善用組成物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2147678A1 (en) * | 2008-07-21 | 2010-01-27 | Nestec S.A. | Probiotics to increase IgA secretion in infants born by caesarean section |
CN108367034A (zh) * | 2015-10-19 | 2018-08-03 | 株式会社明治 | 面向婴儿的感染防御剂 |
EP3443969B1 (en) * | 2016-04-13 | 2021-12-22 | Meiji Co., Ltd. | Use of bifidobacteria for improving developmental quotient in neonates |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02280059A (ja) * | 1989-04-21 | 1990-11-16 | Yakult Honsha Co Ltd | IgA誘導能を有するビフィドバクテリウム・ロンガム又はビフィドバクテリウム・ブレーベ |
JPH04342533A (ja) * | 1991-05-16 | 1992-11-30 | Yakult Honsha Co Ltd | IgA産生促進剤 |
JPH0761934A (ja) * | 1993-08-25 | 1995-03-07 | Yakult Honsha Co Ltd | ワクチンの効果増強剤及び効果増強食品 |
JP2002255853A (ja) * | 2001-03-01 | 2002-09-11 | Biofuerumin Seiyaku Kk | 免疫賦活組成物 |
JP2004262773A (ja) * | 2003-02-17 | 2004-09-24 | Ryoshoku Kenkyukai | 免疫機能改善を目的としたビフィズス菌製剤 |
JP2005089388A (ja) * | 2003-09-18 | 2005-04-07 | Biofuerumin Seiyaku Kk | 免疫賦活作用増強剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0769907A (ja) | 1993-08-27 | 1995-03-14 | Meiji Milk Prod Co Ltd | 日和見感染症防御用組成物 |
JPH07106142A (ja) | 1993-09-29 | 1995-04-21 | Taiyo Yuden Co Ltd | トロイダルコイル |
JP4624574B2 (ja) * | 2000-05-31 | 2011-02-02 | 株式会社ヤクルト本社 | 脂質過酸化抑制剤 |
JP2003201239A (ja) | 2001-11-05 | 2003-07-18 | Meiji Milk Prod Co Ltd | 免疫賦活食品組成物 |
US7179460B2 (en) | 2002-12-05 | 2007-02-20 | Danisco A/S | Bacterial composition and its use |
-
2006
- 2006-02-01 US US11/815,136 patent/US7943124B2/en active Active
- 2006-02-01 CA CA2596680A patent/CA2596680C/en not_active Expired - Fee Related
- 2006-02-01 WO PCT/JP2006/301661 patent/WO2006087913A1/ja active Application Filing
- 2006-02-01 AU AU2006215205A patent/AU2006215205B2/en not_active Ceased
- 2006-02-01 EP EP06712804.1A patent/EP1854467B8/en not_active Not-in-force
- 2006-02-01 CN CN2006800104644A patent/CN101151041B/zh active Active
- 2006-02-01 JP JP2007503610A patent/JP5001830B2/ja active Active
- 2006-02-01 KR KR1020077020013A patent/KR101234435B1/ko active IP Right Grant
-
2008
- 2008-06-25 HK HK08107058.6A patent/HK1116667A1/xx not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02280059A (ja) * | 1989-04-21 | 1990-11-16 | Yakult Honsha Co Ltd | IgA誘導能を有するビフィドバクテリウム・ロンガム又はビフィドバクテリウム・ブレーベ |
JPH04342533A (ja) * | 1991-05-16 | 1992-11-30 | Yakult Honsha Co Ltd | IgA産生促進剤 |
JPH0761934A (ja) * | 1993-08-25 | 1995-03-07 | Yakult Honsha Co Ltd | ワクチンの効果増強剤及び効果増強食品 |
JP2002255853A (ja) * | 2001-03-01 | 2002-09-11 | Biofuerumin Seiyaku Kk | 免疫賦活組成物 |
JP2004262773A (ja) * | 2003-02-17 | 2004-09-24 | Ryoshoku Kenkyukai | 免疫機能改善を目的としたビフィズス菌製剤 |
JP2005089388A (ja) * | 2003-09-18 | 2005-04-07 | Biofuerumin Seiyaku Kk | 免疫賦活作用増強剤 |
Non-Patent Citations (3)
Title |
---|
HOSONO A. ET AL.: "Men'ekikei tp Sogosayo suru Chonai Saikin (Probiotics)", ALLERGOLOGY, vol. 18, no. 6, 2004, pages 483 - 489, XP003001289 * |
KO E.J. ET AL.: "BIFIDOBACTERIUM BIFIDUM EXHIBITS A LIPOPOLYSACCHARIDE-LIKE MITOGENIC ACTIVITY FOR MURINE B LYMPHOCYTES", JOURNAL OF DAIRY SCIENCE, vol. 82, no. 9, 1999, pages 1869 - 1876, XP003001288 * |
PARK J.H. ET AL.: "ENCAPSULATED BIFIDOBACTERIUM BIFIDUM POTENTIATES INTESTINAL IGA PRODUCTION", CELL IMMUNOL., vol. 219, no. 1, 2002, pages 22 - 27, XP003001287 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011525484A (ja) * | 2008-06-24 | 2011-09-22 | ネステク ソシエテ アノニム | プロバイオティクス、分泌型IgA及び感染症 |
JP2011525483A (ja) * | 2008-06-24 | 2011-09-22 | ネステク ソシエテ アノニム | プロバイオティクス、分泌型IgA及び炎症 |
WO2012029367A1 (ja) | 2010-08-31 | 2012-03-08 | 国立大学法人新潟大学 | 腸管免疫調整剤 |
US8980289B2 (en) | 2010-08-31 | 2015-03-17 | Niigata University | Intestine immunomodulator |
WO2014119605A1 (ja) * | 2013-01-29 | 2014-08-07 | 日東薬品工業株式会社 | ビフィズス菌を含有する安定な組成物 |
JPWO2016194692A1 (ja) * | 2015-05-29 | 2018-03-22 | 株式会社明治 | 抗う蝕剤及び抗う蝕用組成物 |
WO2016194692A1 (ja) * | 2015-05-29 | 2016-12-08 | 株式会社明治 | 抗う蝕剤及び抗う蝕用組成物 |
US10517907B2 (en) | 2015-05-29 | 2019-12-31 | Meiji Co., Ltd. | Anticariogenic agent and anticariogenic composition |
WO2018190407A1 (ja) * | 2017-04-14 | 2018-10-18 | 株式会社明治 | Toll様受容体2活性化用組成物 |
WO2020009135A1 (ja) * | 2018-07-03 | 2020-01-09 | 学校法人北里研究所 | インフルエンザの重症化を抑制するための抗インフルエンザウイルス剤 |
CN112351693A (zh) * | 2018-07-03 | 2021-02-09 | 学校法人北里研究所 | 用于抑制流感的重症化的抗流感病毒剂 |
JPWO2020009135A1 (ja) * | 2018-07-03 | 2021-07-15 | 学校法人北里研究所 | インフルエンザの重症化を抑制するための抗インフルエンザウイルス剤 |
JP2022552721A (ja) * | 2019-10-18 | 2022-12-19 | ゲノム アンド カンパニー | ビフィドバクテリウム・ビフィダムを含む免疫力増強または改善用組成物 |
JP7408070B2 (ja) | 2019-10-18 | 2024-01-05 | ゲノム アンド カンパニー | ビフィドバクテリウム・ビフィダムを含む免疫力増強または改善用組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2596680C (en) | 2013-06-18 |
EP1854467A4 (en) | 2011-11-16 |
EP1854467A1 (en) | 2007-11-14 |
JP5001830B2 (ja) | 2012-08-15 |
CN101151041A (zh) | 2008-03-26 |
US20090142374A1 (en) | 2009-06-04 |
AU2006215205A1 (en) | 2006-08-24 |
CN101151041B (zh) | 2012-12-05 |
AU2006215205B2 (en) | 2011-05-19 |
EP1854467B1 (en) | 2018-08-15 |
JPWO2006087913A1 (ja) | 2008-07-03 |
HK1116667A1 (en) | 2009-01-02 |
EP1854467B8 (en) | 2018-09-26 |
US7943124B2 (en) | 2011-05-17 |
KR20070100413A (ko) | 2007-10-10 |
CA2596680A1 (en) | 2006-08-24 |
KR101234435B1 (ko) | 2013-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5001830B2 (ja) | 免疫賦活用組成物 | |
KR102028744B1 (ko) | 면역증강 활성, 항산화 활성 및 소화액 내성을 갖는 락토바실러스 플란타룸 hy7717 균주 및 그의 용도 | |
CN107075455B (zh) | 具有抗炎症及代谢疾病改善功效的植物乳杆菌hac01菌株及其用途 | |
JP6420535B2 (ja) | IgA産生促進作用を有する新規乳酸菌及びその用途 | |
JP5261617B2 (ja) | 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料 | |
KR101088685B1 (ko) | 락토바실러스 펜토서스를 포함하는 면역조절작용을 갖는조성물 | |
KR102001074B1 (ko) | 충치 억제 활성을 갖는 유산균 조성물 | |
WO2018168449A1 (ja) | ペプチドグリカン認識タンパク質産生促進用組成物 | |
JP2020092704A (ja) | 新規な乳酸菌株およびそれを含む免疫賦活剤 | |
CN111212575A (zh) | 肌肉增量用组合物 | |
TW200804591A (en) | Lactic acid bacterium having immunoregulatory activity derived from moromi for wine fermentation | |
JP7436358B2 (ja) | 母乳成分増強用組成物 | |
JP2019097544A (ja) | 新規ビフィドバクテリウム属細菌及び当該細菌を含む組成物 | |
TW201609120A (zh) | 含乳酸菌之腸道屏障功能促進劑 | |
WO2020067422A1 (ja) | T細胞を活性化するための組成物 | |
JP5603036B2 (ja) | プロバイオティクス増殖促進剤 | |
JP6016326B2 (ja) | 乳酸菌のスクリーニング方法 | |
JP2021180619A (ja) | 整腸用茶発酵組成物及びその製造方法 | |
WO2017175774A1 (ja) | インターフェロンλ産生促進用組成物及びその製造方法 | |
JP2009254236A (ja) | 新規乳酸菌並びに新規乳酸菌を利用した飲食品及び免疫賦活剤 | |
KR100443080B1 (ko) | 콜레스테롤 저하능을 갖는 스트렙토코커스 페시움 균주 | |
JP2024128968A (ja) | グレリン分泌促進用組成物 | |
JP2024046233A (ja) | 腸管バリアの改善のための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007503610 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2596680 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007501654 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006712804 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200701708 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006215205 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077020013 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3828/CHENP/2007 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2006215205 Country of ref document: AU Date of ref document: 20060201 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006215205 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680010464.4 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2006712804 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11815136 Country of ref document: US |